AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00315341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
Study NCT02023827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAYS Intervention
Description: The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
Study NCT00313872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP
Description: D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre \& Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre \& post hydration (if Mg \<WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
Study NCT00313872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
Study NCT04189952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.
Study NCT04142229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iAPS
Description: The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
Study NCT04142229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-Augmented Pump
Description: Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
Study NCT00735475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Virus Vaccine (Afluria®)
Description: A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
Study NCT00735475 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Licensed Influenza Virus Vaccine (Fluzone®)
Description: A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
Study NCT00662818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant
Description: Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
Study NCT00662818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Paracetamol
Description: Acetaminophen/Paracetamol (500 mg X 2 dosage units)
Study NCT00662818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Telcagepant
Description: Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
Study NCT00662818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Acetaminophen/Paracetamol
Description: Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
Study NCT00924118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
Study NCT02184364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Klimadynon®
Study NCT02184364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of Klimadynon®
Study NCT02184364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Klimadynon®
Study NCT02184364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oestrofeminal®
Study NCT02184364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04369781 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transcutaneous oxygen pressure recording at rest
Description: Recording of limb and chest transcutaneous oxygen pressure
Study NCT04647552 — intervention group
Intervention type: DRUG
Intervention: Drug Steroid
Description: hydrocortisone injection
Study NCT06444204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Description: Rilzabrutinib tablet administered orally
Study NCT02554227 — intervention group
Intervention type: OTHER
Intervention: Cytokine Profile and suPAR
Description: Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
Study NCT03369327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir and daclatasvir
Description: Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:~1. Daclatasvir 30 mg and sofosbuvir 400 mg~2. Daclatasvir 60 mg and sofosbuvir 400 mg~3. Daclatasvir 90 mg and sofosbuvir 400 mg
Study NCT04690894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block - caudal block
Description: the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered
Study NCT01327443 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Description: Nutritional counseling
Study NCT01327443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Under direct supervision
Study NCT04184232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells
Description: Autologous dendritic cells primed with muc-1/wt-1 peptides
Study NCT04184232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of bladder cancer according to the Clinical protocols
Study NCT04184232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment of bladder cancer according to the Clinical protocols
Study NCT01026532 — intervention group
Intervention type: BIOLOGICAL
Intervention: Segmental Allergen Challenge
Description: Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
Study NCT03803839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clodronate
Study NCT03250273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
Study NCT03250273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
Study NCT00978952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Large Diameter Advanta™ V12 Covered Stent
Description: Stent placement
Study NCT02265523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Description: The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
Study NCT01220570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus + Dalotuzumab
Description: Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
Study NCT01220570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
Study NCT01220570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
Study NCT00116181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
Study NCT00116181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
Study NCT01805661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canal Block and Capsular Injection
Description: Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
Study NCT01805661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral with Tibial Nerve Block
Description: Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
Study NCT02262897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
Study NCT03985683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: agility tests
Description: In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
Study NCT03985683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Interventional
Description: Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
Study NCT00560729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Renutryl 500
Study NCT00560729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Generique
Study NCT00560729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Generique + Renutryl 500
Study NCT01865357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI - Clinical and cognitive evaluation
Description: * Clinical evaluation (EDSS, MSFC)~* Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~* Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI
Study NCT01865357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye movement
Description: Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
Study NCT01505920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Description: 10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
Study NCT01505920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine submucosal injection
Description: 2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
Study NCT03629288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose tab
Description: Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning
Study NCT03629288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
Study NCT03373214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1
Description: Na-GST-1/Alhydrogel®
Study NCT03373214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPG 10104
Description: CPG 10104
Study NCT04579809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4 strand technique
Description: 4 strand technique reapir of tendin flexor injury
Study NCT02507791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Charge HR plus weekly phone calls to review physical activity data
Description: Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
Study NCT02507791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Charge HR plus weekly phone calls to review physical activity data
Description: Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
Study NCT04222920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose reduction to 2mg/L
Description: Adalimumab dose reduction aiming drug concentration of 2mg/L
Study NCT04222920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dose reduction to 5mg/L
Description: Adalimumab dose reduction aiming drug concentration of 5mg/L
Study NCT04222920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab
Study NCT04222920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab
Study NCT00607243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: smallpox vaccine CJ-50300
Description: Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
Study NCT03803839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT01843790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
Study NCT01843790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Saline
Description: The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
Study NCT03291288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Commercially available tolbutamide
Study NCT03291288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Commercially available midazolam
Study NCT03291288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: Pexidartinib is formulated as opaque, white, 200-mg capsules
Study NCT02962427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion Block
Study NCT02962427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural blood patch
Study NCT00449839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Aspart
Description: A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted.
Study NCT02586571 — intervention group
Intervention type: BEHAVIORAL
Intervention: Breastfeeding
Description: Breastfeeding at 5.5 months of age (exclusive or partial)
Study NCT00727701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aftercare summary
Description: A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
Study NCT01276379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (m)
Description: FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.
Study NCT01276379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-6 (m)
Description: FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours.
Study NCT01276379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: - 500 mg/m2 i.v. Every 2 weeks.
Study NCT03887949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group VCV
Description: Volume controlled ventilation
Study NCT03887949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group PCV
Description: Pressure controlled ventilation
Study NCT03887949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group PCV-VG
Description: Pressure controlled ventilation with volume guarantee
Study NCT02955732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
Study NCT04648722 — intervention group
Intervention type: PROCEDURE
Intervention: Hemithyroidectomy
Description: We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.